Humane, the ambitious startup behind the Ai Pin device that aimed to one day replace smartphones, agreed to sell parts of its ...

AbbVie's growth thrives on strong earnings, a robust immunology portfolio, and diversification. See why ABBV stock is a ...

It may be early, but some blazing investments have already delivered wealth-altering gains in this young year. The post 3 hot ...

A potent mix of bureaucratic red tape and adverse court rulings is deterring U.S. startups and small businesses from ...

We assign Siegfried a Medium Morningstar Uncertainty Rating. Its business is relatively stable, with high switching costs and good visibility due to long-term customer contracts. However, small ...

Despite a recently-agreed $7.4 billion settlement, the Sackler family has yet to fully account for its role in America's ...

So far, five biosimilars that reference Eylea 2 mg have been approved by the FDA. Alvotech/Teva expect to regulatory approval ...

While the US is a $600 billion pharmaceutical market, the share of these generic is 90 per cent in terms of volume but a low ...

Find out about what's behind the increase of securities class action lawsuits in the biotech industry and how to prevent them ...

Vincent Gaynor remembers, almost to the minute, when he realized his part in birthing the breakthrough gene therapy Zolgensma ...

Sarfaraz K. Niazi, PhD, gives his opinion on how the recent IQVIA report “Assessing the Biosimilar Void in the US” could be ...

For years, conventional wisdom has been that weight loss is a matter of willpower. Those who are overweight or obese just need to try harder to eat less and exercise more. But while diet and ...